Variability in bioavailability of small molecular tyrosine kinase inhibitors
- 22 March 2015
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 41 (5), 412-422
- https://doi.org/10.1016/j.ctrv.2015.03.005
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in Drug DevelopmentJournal of Pharmaceutical Sciences, 2013
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceBiochemical Pharmacology, 2012
- Structural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate PhasesCrystal Growth & Design, 2012
- BDDCS Class Prediction for New Molecular EntitiesMolecular Pharmaceutics, 2012
- First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of PhenolicsJournal of Pharmaceutical Sciences, 2011
- Physiological Parameters for Oral Delivery and in Vitro TestingMolecular Pharmaceutics, 2010
- Marginal increase of sunitinib exposure by grapefruit juiceCancer Chemotherapy and Pharmacology, 2010
- The Role of Transporters in the Pharmacokinetics of Orally Administered DrugsPharmaceutical Research, 2009
- Molecular mechanisms in therapy of acid-related diseasesCellular and Molecular Life Sciences, 2007